1. Initiate pharmacotherapy in low-risk individuals with LDL-C ≥5 mmol/L, or if there is evidence of genetic dyslipidemia (such as familial hypercholesterolemia) (Recommendation Strong, Quality Moderate).
2. Target ≥50% reduction of LDL-C in low-risk individuals for whom treatment is initiated (Recommendation Strong, Quality Moderate).

Values and Preferences

• Less clinical trial evidence in this group of subjects
• Individual practice will vary dependant on wishes of the patient and evaluation of the treating clinician
• Subjects with risk in the higher end of this category can have the risks/benefits of statin therapy discussed and might be offered statin therapy based on their wishes and/or the judicious use of secondary testing
• In low-risk individuals with LDL-C <5 mmol/L and FRS 5-9% monitor patients annually